# US 2025/0017905 A1 · Composition for inhibiting histamine-n-methyltransferase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017905 A1
- Document ID: US20250017905A1
- Status: Published application
- Kind: A1
- Application number: 18/708,426
- Filed: 2022-11-11
- Published: 2025-01-16
- Earliest claimed: 2021-11-17
- Assignees: Suntory Holdings Limited
- Applicants: Suntory Holdings Limited
- Inventors: Makoto Katsube; Hiroshi Watanabe
- Web page: https://patentgrep.com/patent/US20250017905A1

## CPC

- A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine
- A23L 33/175: Amino acids
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention aims to provide a composition for inhibiting histamine-N-methyltransferase. The present invention relates to a composition for inhibiting histamine-N-methyltransferase, containing L-ergothioneine or a salt thereof.

## Claims

### Claim 1

A composition for inhibiting histamine-N-methyltransferase, comprising
L-ergothioneine or a salt thereof.

### Claim 2 (depends on 1)

The composition according to claim 1,
wherein the composition is an oral composition.

### Claim 3 (depends on 1)

The composition according to claim 1,
wherein the composition is a food or beverage.

### Claim 4 (depends on 1)

The composition according to claim 1 for use in preventing or ameliorating attention deficit/hyperactivity disorder or for increasing appetite.

### Claim 5

A method of inhibiting histamine-N-methyltransferase, the method comprising
administering L-ergothioneine or a salt thereof.

### Claim 6

Use of L-ergothioneine or a salt thereof for inhibiting histamine-N-methyltransferase.
